IP Library Granted Patent US 11,260,070
Granted Patent B2
US 11,260,070 · App. 16/852,102 · Granted Mar 1, 2022

Methods of treating feline coronavirus infections

Inventors: Michel Joseph Perron (Morgan Hill, CA); Niels C Pedersen (Oakland, CA)
Assignees: Gilead Sciences, Inc.; The Regents of the University of California
A61K31/706A61P31/12A61P31/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,070
App. No.
16/852,102
Granted
Mar 1, 2022
Kind
B2
Abstract

Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1′-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.

Claims (10)

1. A method of treating a feline Coronavirus infection in a cat in need thereof, comprising administering to the cat a pharmaceutical formulation comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the pharmaceutical formulation comprises a compound of formula:

3. The method of claim 1 , wherein the feline Coronavirus is feline enteric coronavirus (FECV) or feline infectious peritonitis virus (FIPV).

4. The method of claim 3 , wherein the feline Coronavirus is feline enteric coronavirus (FECV).

5. The method of claim 3 , wherein the feline Coronavirus is feline infectious peritonitis virus (FIPV).

6. The method of claim 1 , wherein the cat has tested positive for feline Coronavirus infection.

7. The method of claim 1 , wherein the cat is showing symptoms for feline Coronavirus infection.

8. The method of claim 1 , wherein the administering comprises oral, rectal, nasal, pulmonary, topical, vaginal, or parenteral administration.

9. The method of claim 1 , wherein the administering comprises subcutaneous, intramuscular, intravenous, intradermal, intrathecal, or epidural administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: PERRON, MICHEL JOSEPH
To: GILEAD SCIENCES, INC.
Reel/Frame 052576/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2020
From: PEDERSEN, NIELS C.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 052576/0786 →
Continuity (3)
Continuation 15919750 · Mar 13, 2018
Provisional Application 62470944 · Mar 14, 2017
Related Publication 20200376014A1 · Dec 3, 2020
Cited By (6)
US 12,297,226 US 12,357,577 US 12,404,289 US 12,448,383 US 12,509,466 US 12,655,172